Eli Lilly And Company · NYSE:LLY

Eli Lilly And — Corporate Update (March 2007)

16 slides from Eli Lilly And's corporate update, Mar 22, 2007

  1. Slide 1: The Lilly MDR-TB Partnership

    The Lilly MDR-TB Partnership

  2. Slide 2: Tuberculosis (TB) Facts

    Tuberculosis (TB) Facts • TB kills 2 million people every year (5000 every day) mostly adults between 15-54 years old • 2 billion people are infected with TB worldwide • 1 in 10 of these people will become sick with active TB • 12 million people worldwide are co-infected with HIV & TB (1/3 of PLWHA*

  3. Slide 3: Estimated incidence of MDR-TB (2003)

    Estimated incidence of MDR-TB (2003)* 650'000 600'000 550'000 500'000 450'000 400'000 350'000 300'000 250'000 200'000 150'000 100'000 50'000 0 Total China + India China India Russian + Russian Federation Federation *Source: WHO 3/22/2007 Copyright© 2007 Eli Lilly and Company 3 MDR-TB Partnership

  4. Slide 4: MDR-TB Challenge

    MDR-TB Challenge • The required prolonged and more expensive treatment results in poor patient compliance and development of resistance; thus the need for intensive directly observed treatments (DOTS-Plus) Lilly’s Response to MDR-TB • Work with public/private partners, health professionals, business

  5. Slide 5: When Lilly Engagement Started

    When Lilly Engagement Started • Partners in Health’s (PIH) sister organization Socios en Salud (SES) working in shantytown north of Lima • 1992: US-PIH worker returns to Boston and dies of MDR-TB • TB resistant to at least isoniazid (INH) and rifampin (RIF) • Investigation of treatment failures reve

  6. Slide 6: Answering the public health community call

    Answering the public health community call In 2003, Lilly decided to develop a comprehensive initiative VISION: to combat encompassing the growing MDR-TB • Transfer of technology pandemic and • Drug supply at concessionary prices • Training tools for health care support the Global professionals/trai

  7. Slide 7: The Lilly MDR-TB Partnership

    The Lilly MDR-TB Partnership US$ 120m multi-faceted program to combat the growing MDR-TB pandemic and meet the WHO goal of treating 20,000 patients annually by the year 2010. Training, Treatment & Surveillance Technology Transfer & Drug Lilly Community Supply Partnership Support Reaching Workplace p

  8. Slide 8: Transfer of Technology and Drug Supply

    Transfer of Technology and Drug Supply • Share all Lilly’s specific and • Offer manufacturing firms in MDR- general manufacturing knowledge. TB “hot spots” the technology to • Create self-sustaining centers of produce capreomycin and manufacturing excellence capable cycloserine and provide training

  9. Slide 9: The Lilly MDR-TB Partnership

    The Lilly MDR-TB Partnership Purdue University ( Indiana, USA) • Assists in technology transfer by providing training and certification in business management and good manufacturing practices for Lilly’s international drug manufacturing partners. • Increases drug supply by producing additional quant

  10. Slide 10: The Lilly MDR-TB Partnership

    The Lilly MDR-TB Partnership 3/22/2007 Copyright© 2007 Eli Lilly and Company 10 MDR-TB Partnership

  11. Slide 11: Training, Treatment & Surveillance

    Training, Treatment & Surveillance World Health Organization Dr. Paul Farmer, chief of the Division of Social • Provide technical support and monitor drug resistance Medicine and Health Inequalities at Brigham and Woman’s Hospital and a co-founder of to first-line TB drugs Partners in Health, examin

  12. Slide 12: Awareness and Prevention in the Workplace

    Awareness and Prevention in the Workplace World Economic Forum • Develop a Global Awareness Toolkit for Tuberculosis/MDR-TB in the Workplace and disseminate through WEF member companies • Provide educational material targeting employees and in-plant health care staff • Pilot tested in India and adap

  13. Slide 13: Community Support and Patient Advocacy

    Community Support and Patient Advocacy International Federation of the Red Cross & Red Crescent Societies • Community support to MDR-TB patients to ensure better access to care and improved compliance • Educational programs to improve community awareness of preventative measures and stigma reduction

  14. Slide 14: Global Partners - Local Action

    Global Partners - Local Action 3/22/2007 Copyright© 2007 Eli Lilly and Company 14 MDR-TB Partnership

  15. Slide 15: Lilly's Impact

    Lilly’s Impact • From 2000 to 2006, Lilly supplied approximately one million vials of capreomycin and 5 million capsules of cycloserine through the WHO’s DOTS-Plus program in 40 GLC-approved countries. • Lilly’s transfer of technology will ensure a greater supply of affordable, quality, second-line

  16. Slide 16: Contact Information

    Contact Information Patrizia Carlevaro Head of International Aid Unit Eli Lilly and Company Geneva, Switzerland +41- 22-306-0394 carlevaro_pat@lilly.com www.lilly.com www.lillymdr-tb.com 3/22/2007 Copyright© 2007 Eli Lilly and Company 16 MDR-TB Partnership

Eli Lilly and Company — Corporate Update (March 2007) on 6ix